Neurometrix Inc (NURO) Stock Price, Quote & News

Company Profile

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatrists, primary care physicians, and other clinicians at the point-of care to objec...

Industry: Medical Devices

Sector: Healthcare

Phone: 781 890 9989

Website: www.neurometrix.com

Address:

4B Gill Street, Woburn, United States

macrossluvsrobotech Jan. 5 at 11:18 PM

$BB + $LCID + $UBER + $NURO + $NVDA Gemini3Pro= "The announcement of the Lucid-Nuro-Uber robotaxi alliance at CES 2026 is effectively a "paid advertisement" for the QNX ecosystem. Here is the breakdown of why this specific partnership drives revenue and validation for BlackBerry: 1. The "Hidden" Tech Stack While the press release highlights Lucid (Car), Nuro (AI), and Uber (Network), the technical reality relies on the "NVIDIA + QNX" standard. The Hardware: Reports from CES confirm the Nuro software runs on the NVIDIA DRIVE AGX platform (likely the Hyperion architecture). The OS: Nuro has historically built its autonomous safety stack on QNX. You cannot run a Level 4 autonomous car on public roads without a safety-certified operating system (ISO 26262), and QNX is the industry standard for that layer. The Connection: Since NVIDIA DRIVE platforms use QNX as the foundational safety OS, this fleet deployment effectively guarantees QNX royalties for every vehicle." https://media.lucidmotors.com/en/newsitem/1061-lucid-nuro-and-uber-unveil-global-robotaxi-at-ces-announce-autonomous-on-road-testing

0 · Reply

kuda8 Nov. 1 at 7:43 AM

$NURO got payment for CVR , a huge 0,0907 € /cvr , my broker has delisted the CVR , disapointed , i thought i could receive the proceeds from sale of DPN Check to Fukuda , and thought the CVR would last until 2030 .

0 · Reply

stocktrade110 Oct. 24 at 3:53 PM

$DVLT It is just a beggining. Hold tight, next year will be great! $NUAI $NURO $NVDA $TSLA

0 · Reply

Chuck4Options Sep. 17 at 9:23 AM

$NURO I’m going to be streaming FOMC all day tomorrow. Chuck4options on you tube! It’s going to be all money talk. Calling strikes and making plays. Play it if you want, or wait till you hear something good. I’m making it a daily thing but today is FOMC day. If who your watching isn’t activity and freely holding your hand to make sure you make money. Then join me on my daily stream! You don’t have to join discord or sign up. Just join the stream and get ready to make tons of cash. Chuck4options

0 · Reply

GermanBulle Sep. 8 at 7:21 PM

$NURO yehaaa

0 · Reply

Heywood_Jablomi Jun. 5 at 1:48 PM

$NURO what the hell has happened here??

0 · Reply

nesanmano May. 22 at 7:45 PM

$NURO guys what is happening

1 · Reply

elohim1oh1 May. 19 at 8:10 PM

$NURO 💪👀

1 · Reply

BioTuesdays May. 2 at 1:59 PM

electroCore announced it has completed the merger with NeuroMetrix, expanding its portfolio to include Quell Fibromyalgia Solution, strengthening its commercial reach, and positioning the company as a diversified leader in non-invasive health and wellness solutions $ECOR $NURO https://biotuesdays.com/2025/05/02/electrocore-acquires-neurometrix-gaining-access-to-quell-platform/

0 · Reply

Rage_Against_The_Machine May. 2 at 12:36 PM

$NURO merger officially closed - shares converted to $4.49 cash + contingent value rights. Trading halted as stock delists. Final chapter for the once-promising neurotech play. Now it's all about execution on those Quell sales milestones through 2030. CVRs = lottery tickets with better odds than most biotechs. https://www.sec.gov/Archives/edgar/data/1289850/000164117225008179/form8-k.htm

0 · Reply

NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO

Dec 17, 2024, 4:05 PM EST - 1 year ago

NeuroMetrix to be Acquired by electroCore

Aug 13, 2024, 2:47 PM EDT - 1 year ago

NeuroMetrix Reiterates its Review of Strategic Alternatives

Jul 31, 2024, 2:03 PM EDT - 1 year ago

NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

May 15, 2024, 4:00 PM EDT - 2 years ago

NeuroMetrix Reports Q1 2024 Business Highlights

Apr 19, 2024, 8:00 AM EDT - 2 years ago

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

Mar 14, 2024, 9:00 AM EDT - 2 years ago

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

Mar 13, 2024, 9:00 AM EDT - 2 years ago

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

Mar 4, 2024, 8:00 AM EST - 2 years ago

Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.

Feb 22, 2024, 7:00 AM EST - 2 years ago

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

Feb 15, 2024, 9:00 AM EST - 2 years ago

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

Feb 13, 2024, 9:00 AM EST - 2 years ago

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

Jan 8, 2024, 9:43 AM EST - 2 years ago

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

Dec 12, 2023, 9:00 AM EST - 2 years ago

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

Dec 5, 2023, 9:00 AM EST - 2 years ago

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

Nov 20, 2023, 9:00 AM EST - 2 years ago

NeuroMetrix Announces One-for-Eight Reverse Stock Split

Oct 30, 2023, 9:00 AM EDT - 2 years ago

NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023

Oct 26, 2023, 7:00 AM EDT - 2 years ago

NeuroMetrix Reports Q3 2023 Business Highlights

Oct 23, 2023, 11:13 AM EDT - 2 years ago

NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call

Oct 2, 2023, 9:00 AM EDT - 2 years ago

NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia

Sep 28, 2023, 12:19 PM EDT - 2 years ago

NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023

Aug 30, 2023, 9:00 AM EDT - 2 years ago

NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023

Jul 27, 2023, 7:00 AM EDT - 2 years ago

NeuroMetrix Reports Q2 2023 Business Highlights

Jul 20, 2023, 1:00 PM EDT - 2 years ago

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

Jul 11, 2023, 9:00 AM EDT - 2 years ago

NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia

Jun 28, 2023, 9:00 AM EDT - 3 years ago

Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients

Jun 7, 2023, 9:00 AM EDT - 3 years ago

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

May 31, 2023, 9:00 AM EDT - 3 years ago

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

May 3, 2023, 7:00 AM EDT - 3 years ago

NeuroMetrix Reports Q1 2023 Financial Results

Apr 28, 2023, 9:21 AM EDT - 3 years ago

NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call

Mar 21, 2023, 9:00 AM EDT - 3 years ago

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

Feb 23, 2023, 7:00 AM EST - 3 years ago

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

Feb 16, 2023, 2:58 PM EST - 3 years ago

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call

Jan 23, 2023, 9:00 AM EST - 3 years ago

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Nov 8, 2022, 9:00 AM EST - 3 years ago

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

Oct 20, 2022, 7:00 AM EDT - 3 years ago

NeuroMetrix Reports Q3 2022 Financial Results

Oct 12, 2022, 3:47 PM EDT - 3 years ago

NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call

Sep 1, 2022, 9:00 AM EDT - 3 years ago

NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

Jul 21, 2022, 7:00 AM EDT - 4 years ago

NeuroMetrix Reports Q2 2022 Financial Results

Jul 14, 2022, 11:32 AM EDT - 4 years ago

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call

Jun 28, 2022, 9:00 AM EDT - 4 years ago

NeuroMetrix Appoints Brad Fluegel to its Board of Directors

May 19, 2022, 5:35 PM EDT - 4 years ago

6 Stocks Halted In Thursday's Session: Here's Why

May 19, 2022, 10:56 AM EDT - 4 years ago

Why NeuroMetrix Shares Are Skyrocketing

May 19, 2022, 9:00 AM EDT - 4 years ago

NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

Apr 26, 2022, 7:00 AM EDT - 4 years ago

NeuroMetrix Reports Q1 2022 Financial Results

Apr 19, 2022, 9:00 AM EDT - 4 years ago

NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call

Feb 24, 2022, 9:21 AM EST - 4 years ago

NeuroMetrix's Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome

Feb 24, 2022, 9:00 AM EST - 4 years ago

NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome

macrossluvsrobotech Jan. 5 at 11:18 PM

0 · Reply

kuda8 Nov. 1 at 7:43 AM

0 · Reply

stocktrade110 Oct. 24 at 3:53 PM

$DVLT It is just a beggining. Hold tight, next year will be great! $NUAI $NURO $NVDA $TSLA

0 · Reply

Chuck4Options Sep. 17 at 9:23 AM

0 · Reply

GermanBulle Sep. 8 at 7:21 PM

$NURO yehaaa

0 · Reply

Heywood_Jablomi Jun. 5 at 1:48 PM

$NURO what the hell has happened here??

0 · Reply

nesanmano May. 22 at 7:45 PM

$NURO guys what is happening

1 · Reply

elohim1oh1 May. 19 at 8:10 PM

$NURO 💪👀

1 · Reply

BioTuesdays May. 2 at 1:59 PM

0 · Reply

Rage_Against_The_Machine May. 2 at 12:36 PM

0 · Reply

leosp11 Mar. 31 at 9:06 PM

$NURO AI suggests buy here

0 · Reply

NVDAMillionaire Mar. 29 at 7:05 PM

$NURO Quell tech looks promising. Digging into their fibromyalgia and CIPN potential. Might be an undervalued play in chronic pain management. FDA breakthrough designation gives some credibility. Watching closely for next moves in strategic review. great article: https://beyondspx.com/article/neurometrix-nuro-a-pioneering-medtech-navigating-challenges-in-chronic-pain-and-neuropathy-diagnostics

0 · Reply

PenkeInvesting Mar. 25 at 12:06 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of NeuroMetrix Inc. Is that bullish or bearish? $NURO #NeuroMetrix #RsiOverbought #NASDAQ

0 · Reply

theshortsqueezer2022 Mar. 24 at 9:29 PM

$TNON I missed out on $NURO in 2021 but this time I’m fully loaded

1 · Reply

theshortsqueezer2022 Mar. 23 at 10:35 PM

$NURO buyout any time soon

0 · Reply

NVDAMillionaire Jan. 26 at 4:21 AM

$NURO NeuroMetrix, Inc. (NASDAQ:NURO): Navigating Challenges and Exploring Strategic Alternatives https://beyondspx.com/article/neurometrix-nasdaq-nuro-a-pioneer-in-neurostimulation-and-diagnostics-navigating-a-shifting-market-landscape

0 · Reply